[
    [
        {
            "time": "",
            "original_text": "最高暴涨200倍！空间巨大的中小市值龙头，持续高增长股名单出炉",
            "features": {
                "keywords": [
                    "暴涨",
                    "中小市值",
                    "龙头",
                    "高增长",
                    "股名单"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "最高暴涨200倍！空间巨大的中小市值龙头，持续高增长股名单出炉",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业2020年中期策略：医药节奏看疫情 重点细分看“科技”自下而上填洼地",
            "features": {
                "keywords": [
                    "医药",
                    "疫情",
                    "科技",
                    "细分",
                    "洼地"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2020年中期策略：医药节奏看疫情 重点细分看“科技”自下而上填洼地",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "视点 |《柳叶刀》子刊：回眸35年来FDA抗微生物新药审评、审批",
            "features": {
                "keywords": [
                    "柳叶刀",
                    "FDA",
                    "抗微生物",
                    "新药",
                    "审评",
                    "审批"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "视点 |《柳叶刀》子刊：回眸35年来FDA抗微生物新药审评、审批",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        }
    ]
]